Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.
Summary
This bill would change how NJ FamilyCare pays for long-acting injectable antipsychotic drugs when they are administered in an inpatient hospital setting. It requires that reimbursement for these drugs be separate from the hospital’s general inpatient payment under the Diagnostic Related Group (DRG) system, and it sets the inpatient reimbursement rate equal to the rate paid for the same drug in an outpatient setting. The bill does not change whether the drugs are covered under NJ FamilyCare; it only changes how providers are paid for them.
The bill also authorizes pharmacists to administer a long-acting injectable antipsychotic drug to a patient under a prescription from an authorized prescriber, so long as the pharmacist is properly trained and qualified under standards set by the State Board of Pharmacy and rules jointly adopted with the State Board of Medical Examiners. In addition, the Commissioner of Human Services would have to seek any necessary federal approvals or waivers and adopt implementing regulations.
Impact
The bill would amend NJ FamilyCare reimbursement policy for Medicaid and CHIP-covered inpatient services by carving long-acting injectable antipsychotic drugs out of the DRG-based inpatient payment structure and tying inpatient payment to the outpatient drug rate. This would likely increase reimbursement to hospitals and other inpatient providers that administer these medications, while requiring the Department of Human Services to pursue federal Medicaid approvals and promulgate rules. It would also expand the practical authority for pharmacists to administer these injectable psychiatric medications under specified training and regulatory conditions.
Sentiment
The bill appears generally supportive of access to treatment and provider reimbursement, with the statement emphasizing clinical benefits such as improved adherence, fewer hospitalizations, and better outcomes. The absence of recorded committee testimony or votes means there is no documented opposition or support in the provided history, but the bill’s framing suggests a policy goal of aligning payment with drug cost and reducing barriers to treatment. Overall, the available materials indicate a favorable posture toward the bill’s objectives.
Contention
The main policy issue is reimbursement methodology: hospitals and other inpatient providers may support the bill because DRG payments may not adequately account for the high cost of these drugs, while payers or budget-conscious stakeholders could object to higher or separate payments. Another potential point of contention is the pharmacist-administration provision, which may raise questions about scope of practice, training standards, and patient safety. No specific opposition is recorded in the provided materials, so these are the likely areas of debate rather than documented disputes.